Product Images Bortezomib
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 12 images provide visual information about the product associated with Bortezomib NDC 55150-337 by Eugia Us Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Formula 1 - bortezomib fig1
This text provides instructions on how to calculate the required volume of Bortezomib medication to be administered to a patient based on their body surface area (BSA) and the injection dose. The calculation involves multiplying the injection dose in milligrams per square meter of body surface area by the patient's BSA to obtain the total Bortezomib volume in milliliters to be administered. The concentration of the medication is 1 milligram per milliliter. This information is useful for healthcare professionals who are involved in the administration of Bortezomib in clinical settings.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-3.5 mg per Vial - Container-Carton (1 Vial) - bortezomib fig10
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-3.5 mg per Vial - Sticker Label - bortezomib fig11
Formula 1 - bortezomib fig2
This is a calculation for determining the total volume of Bortezomib to be administered to a patient based on their dose (mg/m') and body surface area (m²). The concentration of Bortezomib for injection is 2.5 mg/mL.*
Figure 1: Time to Progression Bortezomib, Melphalan and Prednisone vs Melphalan and Prednisone - bortezomib fig3
Figure 2: Overall Survival Bortezomib, Melphalan and Prednisone vs Melphalan and Prednisone - bortezomib fig4
Figure 3: Time to Progression Bortezomib vs Dexamethasone (Relapsed Multiple Myeloma Study) - bortezomib fig5
Figure 4: Overall Survival Bortezomib vs Dexamethasone (Relapsed Multiple Myeloma Study) - bortezomib fig6
bortezomib-fign7 - bortezomib fig7
bortezomib-fign8 - bortezomib fig8
The text appears to be a chart or a graph that displays the number of subjects at risk over a period of months from randomization for two treatment groups named VGR-CAP and R-CHOP. The values in the chart represent the number of subjects in each group after a certain number of months. The description also indicates that there is a comparison between the two treatment groups.*
PACKAGE LABEL-PRINCIPAL DISPLAY PANEL-3.5 mg per Vial - Container Label - bortezomib fig9
This is a medication with the code N35, containing 35g of bortezomib and 35g of mannitol, intended for intravenous or subcutaneous use. It is stored at a temperature of 20° to 25°C and should be protected from light. It is made and sold by AuroMedics Pharma LLC in E. Windsor, NJ. Dosage information can be found in the accompanying package insert.*
Chemical Structure - bortezomib str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.